the First Hospital of Jilin University
Changchun, Jilin, 130000, China
Location status: Recruiting
Location contact
Yi Yang
CONTACT
NCT Number: NCT05028855
In this multi-center prospective observational study within a cohort of symptomatic cerebral atherosclerotic stenosis (sCAS) patients, 850 subjects were planed to be enrolled to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Changchun, Jilin, 130000, China
Location status: Recruiting
Yi Yang
CONTACT
Ischemic stroke is a tremendous public health burden that seriously endangers the health of Chinese population symptomatic cerebral atherosclerotic stenosis (sCAS) is responsible for about 33-50% of ischemic stroke in China and highly associated with the risk of stroke recurrence.
Cerebral autoregulation (CA) is the main protective mechanism that modulates cerebral blood flow to satisfy regional cerebral perfusion demands despite of variations in arterial blood pressure (ABP). Thus, CA supposed to be particularly considered when choosing individual therapeutic strategy in sCAS patients. In clinical practice, applying transcranial Doppler combined with servo-controlled plethysmograph assessing CA has been proved a feasible method in cerebral atherosclerotic stenosis patients. Especially in those severe stenosis patients, CA is probably compromised in varying degrees, whereas whether and to what extent CA parameters have the capability to predict stroke recurrence has not been illustrated.
Thus, the aim of the study was to assess CA after acute ischemic stroke or transient ischemic attack within 2 years follow-up to explore the relationship between CA and stroke recurrence and determine the threshold values of CA parameter to predict stroke recurrence. CA measurement will be performed at 0-3 and 10-30 days after ischemic cerebrovascular events. Clinical information, neuroimaging data, biochemical examinations and follow-up information will be collected and recorded in case report form (CRF) once signing of informed consent.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
Time frame: two years
Ischemic cerebrovascular recurrence (TIA or ischemic stroke) within cerebral stenotic artery supplying area diagnosed by symptoms and imaging examinations.
Time frame: within 30 days ischemic cerebrovascular events onset
Phase difference, gain and coherence of symptomatic cerebral atherosclerotic stenosis patients within 30 days ischemic cerebrovascular events onset.
Time frame: two years
All ischemic cerebrovascular recurrence (TIA or ischemic stroke) within two years follow-up diagnosed by symptoms and imaging examinations.
Time frame: two years follow-up
The composite endpoint events include fatal and nonfatal stroke (ischemic or hemorrhagic stroke), fatal and nonfatal myocardial infarction, transient ischemic attack (TIA) diagnosed by symptoms and imaging examinations.
Time frame: two years
The changes of mRS and Barthel score within 2 years
Time frame: two years follow-up
The first onset time of each individual part of composite endpoint events within 2 years
Time frame: within 1 month
The changes of NIHSS score from admission to discharge
Contact information is provided by the study sponsor or research team.
Yi Yang, MD, PhD
CONTACT
Zhenni Guo, MD
CONTACT
Yi Yang
Other
Acronym: CASCAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02639806
Brain Diseases, Brain Ischemia
Saskatoon, Saskatchewan, Canada
View Trial DetailsNCT03417349
Brain Diseases, Cardiovascular Diseases
Linz, Austria
View Trial DetailsNCT02478177
Brain Diseases, Cardiovascular Diseases
Durham, North Carolina, United States
View Trial DetailsNCT02725944
Arrhythmias, Cardiac, Atrial Fibrillation
Oslo, Akershus, Norway
View Trial Details